Finding treatment targets in advanced gastric cancer
Part of Cancer, Digestive system clinical trials.
This study looks for specific genetic or molecular markers in advanced gastric cancer that has spread to other parts of the body. The goal is to identify which treatments might work best for each patient's individual cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–80 years old
- Your gastric (stomach) cancer has spread to lymph nodes or distant sites like liver, lungs, bones, or abdomen
- You are planning to receive chemotherapy, targeted therapy, or immunotherapy (either before surgery or for symptom management)
- You are able to give written permission to participate
- Your overall health status allows you to tolerate treatment (WHO performance score of 2 or better)
- You are not pregnant or breastfeeding, and do not have a severe blood-clotting disorder
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination treatment for advanced or metastatic stomach cancer (that is MSS/pMMR and HER2-negative) that has not been treated before. The treatment combines a short course of radiation (targeted to lymph nodes) with first-line therapy and a PD-1 inhibitor (a type of immunotherapy) to see if it can help control the cancer and improve outcomes.
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests whether a minimally invasive camera-guided surgical procedure (laparoscopy) can better detect hidden cancer spread in patients with advanced stomach cancer. The goal is to help doctors plan the best treatment and improve outcomes.
Hear when a new Stomach Neoplasms, Benign trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.